Ayala Pharmaceuticals Inc (ADXS)

[bill_y]

seems to me this company has been moving towards the precipus of game changing cancer treatment with its programmable listeria vector that can target specific, unique markers on the cancer cell..the technology was worth 500million from amgen + full trial expenses, 300 million from selene, 10 million from stenhal and interest from merck for psa, astra for cervical, head and neck, bmy for cervical.. combine that with our new versatile business model towards big pharma and its own current p3 trials as well as the pending eu submission and a 160 million market cap seems undervalued to me..and while the HER2 for osteo in dogs will not result in game changing revenue it will result in lm product on the market..and commercial validation of the HER2 construct..with possible licensing revenue..